{"disease":{"id":"egfr-gene-mutation","name":"egfr gene mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04322890","title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hunan Province Tumor Hospital","has_results":false},{"nct_id":"NCT06716580","title":"EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT03175224","title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":497,"lead_sponsor_name":"Apollomics Inc.","has_results":false},{"nct_id":"NCT03653546","title":"First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":492,"lead_sponsor_name":"Alpha Biopharma (Jiangsu) Co., Ltd.","has_results":false},{"nct_id":"NCT04206072","title":"D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":362,"lead_sponsor_name":"Betta Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT04695925","title":"Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":294,"lead_sponsor_name":"Li Zhang, MD","has_results":false},{"nct_id":"NCT04358562","title":"Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"Second Affiliated Hospital of Nanchang University","has_results":false},{"nct_id":"NCT06323148","title":"Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":226,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04592666","title":"Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":226,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03046992","title":"Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":224,"lead_sponsor_name":"Yuhan Corporation","has_results":false},{"nct_id":"NCT05598528","title":"Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)","phase":"","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"Second Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT04862780","title":"(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":177,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT05033691","title":"A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases","phase":"NA","overall_status":"RECRUITING","enrollment_count":162,"lead_sponsor_name":"Hadassah Medical Organization","has_results":false},{"nct_id":"NCT04042558","title":"A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Centre Francois Baclesse","has_results":false},{"nct_id":"NCT06521034","title":"First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Yongchang Zhang","has_results":false},{"nct_id":"NCT04552613","title":"Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","has_results":false},{"nct_id":"NCT06291688","title":"Applying Mobile Healthcare Education to Improve Cutaneous Self-care Capability","phase":"NA","overall_status":"UNKNOWN","enrollment_count":110,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT03042221","title":"Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT05503667","title":"Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT03065387","title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":93,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03066206","title":"Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":93,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03846310","title":"A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Arcus Biosciences, Inc.","has_results":false},{"nct_id":"NCT06238882","title":"Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.","phase":"NA","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"Instituto Nacional de Cancerologia de Mexico","has_results":false},{"nct_id":"NCT06643000","title":"Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT03087071","title":"Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":59,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05698264","title":"A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Nir Peled","has_results":false},{"nct_id":"NCT04201756","title":"Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT07343479","title":"Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT06018688","title":"Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":44,"lead_sponsor_name":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","has_results":false},{"nct_id":"NCT03049618","title":"Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"University of Southern California","has_results":true},{"nct_id":"NCT05517083","title":"Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Pusan National University Hospital","has_results":false},{"nct_id":"NCT02098954","title":"Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Hunan Province Tumor Hospital","has_results":false},{"nct_id":"NCT04882345","title":"Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT04085315","title":"Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"Collin Blakely","has_results":false},{"nct_id":"NCT06117644","title":"The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","has_results":false},{"nct_id":"NCT03396185","title":"Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Betta Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT04013542","title":"Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02629523","title":"Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Chonnam National University Hospital","has_results":false},{"nct_id":"NCT06186401","title":"Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Hideho Okada, MD, PhD","has_results":false},{"nct_id":"NCT05394233","title":"Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Sichuan Cancer Hospital and Research Institute","has_results":false},{"nct_id":"NCT06095934","title":"Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT06071013","title":"Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"China Medical University Hospital","has_results":false},{"nct_id":"NCT05153408","title":"(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT03755102","title":"A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT06222489","title":"Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":16,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT07461727","title":"An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03944265","title":"Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT03732352","title":"18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02947386","title":"Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT04908956","title":"Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"ETOP IBCSG Partners Foundation","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}